Austrian Pitching Day

Austrian Trade Commission | London

26 November 2015

www.advantageaustria.org/uk

The information in this brochure is not intended to constitute a financial promotion for the purposes of Section 21 of the Financial Services and Markets Act 2000 and the Financial Promotion Order 2005 and does not amount to a personal recommendation or advice on the merits of the deal. All investment decisions are made at the risk of the individual investor.

#AustrianPitchingDay

Like facebook.com/startupsgoglobal

Follow @austria_in_uk

Join our ADVANTAGE AUSTRIA in the UK group

ADVANTAGE AUSTRIA London Austrian Embassy – Commercial Section

Deputy Trade Commissioner: Cornelia Reibach-Stambolija

Head of Technology Affairs: Monika Dunkel

Austrian Trade Commission 45 Princes Gate (Exhibition Road) London SW7 2QA United Kingdom T +44 20 7584 4411 F +44 20 7584 2565 E london@advantageaustria.org W advantageaustria.org/uk

PROGRAMME AUSTRIAN PITCHING DAY

4.30pm ARRIVAL

5.00pm – 5.15pm WELCOME

Cornelia Reibach-StambolijaDeputy Trade Commissioner, Austrian Trade Commission

Jenny ToothChief Executive, UK Business Angels Association

5.15pm – 6.15pm PITCHES (7 minute pitch + 3 minute Q&A)

AUROXvisalyze GmbHFresnex GmbHEconob GmbHPhilippeit GmbH

6.15pm – 6.30pm BREAK

6.30pm – 7.30pm PITCHES (7 minute pitch + 3 minute Q&A)

9yards GmbHBraincon Handels-GmbHsofasession GmbHHappyMed GmbHDealMatrix GmbH

7.30pm – 7.45pm ROUND-UP

Bernd Litzka AWS (Austria Wirtschaftsservice)Bernhard Aichinger JW (Junge Wirtschaft)Rafael Rasinger WKO (Austrian Federal Economic Chamber)

From 7.45pm NETWORKING, WINE AND AUSTRIAN FOOD

#AustrianPitchingDay

The wearable medical product named AUROX is used for the treatment of otitis externa (infection of the outer ear canal). The idea behind AUROX is already patented in Austria, and the PCT application (USA, Europe) is in progress and expected to be granted in 2015.

The inflamed ear is cooled from the outside by means of an earplug which con-tains a peltier element. As a result of the cooling of the inflamed ear canal, the patient’s pain is relieved and the healing of the infection supported through reduced swelling. In addition, selective cooling offers an antibacterial effect without any known undesirable side effects.

Clinical testing will be conducted at the university medical centre in Graz by the end of this year. As AUROX is close to production, distribution should be able to begin in 2016.

Previous funds raisedAUROX have received funding from Science Park Graz GmbH and from external investors.

Funding requirementApproximately €195,000 (£140,000) is needed to carry out formal clinical testing and move into serial production.

AUROXAUROXFunding requirement €195,000 (£140,000)Contact Mr Christoph SchögglerE office@aurox.atT +43 664 4495 854W www.aurox.atIncorporation date June 2015Location Graz, Austria

#AustrianPitchingDay

VISALYZE is a cloud based SaaS that helps unveil online strategies and validate or benchmark social media strategies of organisations against those of their compe-tition. Furthermore, this social media tool also helps identify hidden trends from social media activity. VISALYZE’s intuitive approach and the visual presentation of complex data provide users with great insights from social media and online marketing, without them needing to possess great analytical skills.

VISALYZE targets customers who make a living from social media – social media managers, bloggers, PR consultants, journalists, brand managers, agencies and many others – and provides them with ready-made visualisations. Stiegl, Novartis and SOS Kinderdorf are among VISALYZE’s first customers.

Previous funds raisedVISALYZE has already raised some €1.6 million (£1.2 million) from funding bodies (CAST, AWS, FFG) and private investors.

Funding requirementVISALYZE is seeking to raise €1.5 million (£1.1 million) in order to successfully enter the UK and US markets.

visalyze GmbHvisalyzeFunding requirement €1.5 million (£1.1 million)Contact Mr Mario NeururerE mario.neururer@visalyze.comT +43 699 1740 7458W www.visalyze.comIncorporation date June 2012Location Innsbruck, Austria

#AustrianPitchingDay

Based on a new mirror bearing, the so called CSP-PANEL invented by FRESNEX is the first small scale application that enables the collection of solar energy in the form of steam. The mirror module, which is a self-contained unit and ideal for rooftop installation, combines mirrors with drive and control and can be put into operation on site in a short time. In addition to the environmental benefits and image gain, the patented solar field from FRESNEX reduces dependency on the fast-moving commodity prices of fossil fuels and saves money.

The Austrian Institute of Technology (AIT) tested the thermal performance of a fully functional prototype according to the standards for solar collectors (EN 12975). The results confirmed the efficiency of the system indicated by FRESNEX’s own simulations. The first real-world plants to use the technology are already being planned and will be up and running in summer 2016.

Previous funds raisedCosts arising in the product development phase, followed by a phase of first demonstration projects, are largely covered by subsidies (AWS, FFG, EU), private investors, business angels and initial revenues.

Funding requirementAn amount of approximately €6 million (£4.4 million) will be needed until break even can be reached. The company is currently looking for investors to secure the next round of €700,000 (£500,000) investment.

Fresnex GmbHCSP-PanelFunding requirement €700,000 (£500,000)Contact Mr Hartmut SchneiderE hartmut.schneider@fresnex.comT +43 664 4531 043W www.fresnex.comIncorporation date August 2012Location Wiener Neudorf, Austria

Tune Your Future

#AustrianPitchingDay

ECONOB is a NLP (Natural Language Processing) company solving unmet market needs in various niches. They provide “semantic analysis” services and solutions, of the type already common in the finance industry.

Electronic texts – emails, reports, news, memos, social media – contain a huge treasure of hidden information, but separating valuable from irrelevant informa-tion is incredibly time-consuming. This is where ECONOB’s LINGREP technology comes in. This text analysis technology is already market proofed and included in several solutions – notably ATRAP, which reads, analyses and interprets news and subsequently generates fully automatic trades. No other software can do this as quickly and accurately, and ECONOB is already generating revenue with ATRAP.

According to IBM, ECONOB is the most technologically advanced company in Austria.

Previous funds raisedECONOB completed a successful first financing round in 2012, raising €300,000 (£220,000).

Funding requirementECONOB now intends to complete further funding rounds to raise €1.1 million (£0.8 million).

Econob GmbHLingRepFunding requirement €1.1 million (£0.8 million)Contact Mr Markus SchichoE markus.schicho@econob.comT +43 650 4255 624W www.econob.comIncorporation date December 2009Location Klagenfurt, Austria

#AustrianPitchingDay

PHILIPPEIT has developed and marketed the safest and most efficient authenti-cation technology on the market today. Its hand vein scan allows specific human actions to be traced to their originator through the analysis of vein structures. As vein structures are unique, they can be used to differentiate individual persons.

When you hold your hand over the sensor, the internal hand vein pattern of your palm can be picked up by an infrared camera. The vein structure is compared with a reference pattern on disk and the person thus identified. The process is forgery-proof, non-invasive, completely hygienic and capable of being adapted for all sorts of applications.

Two test versions are currently being trialled in Vienna. A third trial in cooperation with the international security company Security & Emergency is also in process. Hannes Jagerhofer, organiser of the BeachVolleyBall Grand Slam in Klagenfurt, incorporated the hand vein scan in the security system that protected the VIP and athletes area of the 2013 competition. In October 2014 Rainer Philippeit won the Lower Austrian Innovation Prize.

Previous funds raisedPHILIPPEIT was able to secure AWS funding worth €150,000 (£110,000) and a loan of €95,000 (£70,000).

Funding requirementPHILIPPEIT needs a further €500,000 (£370,000) to accelerate its market launch.

Philippeit GmbHHandveinscanFunding requirement €500,000 (£370,000)Contact Mr Rainer PhilippeitE office@philippeit.atT +43 650 6912 986W www.handvenentechnologie.comIncorporation date July 2013Location Ebreichsdorf, Austria

#AustrianPitchingDay

9 YARDS is one of Europe’s leading companies in the Mobile OCR (Optical Character Recognition) field. The company is the inventor of the ANYLINE SDK (Software Development Kit), a patented image processing and mobile text recognition tech-nology that makes it easy for smartphones to capture text in video frames and turn it into digital output.

The SDK is implemented by developers on standard smartphones or wearables with a camera and enables applications to scan codes, read values or simply import any kind of digit or text. The ANYLINE SDK focuses on use cases, where data import on mobile devices is difficult. People make mistakes – typing on mobile keyboards is error-prone, voice recognition is often not appropriate, but accuracy is important.

The ANYLINE SDK makes expensive, specialist hardware such as barcode or passport scanners completely obsolete. Companies can use their employees’ or customers’ smartphones or wearables instead, thus saving money and making them more flexible and more efficient.

Previous funds raisedTo date, the development of ANYLINE has been financed using revenues from 9YARDS’ mobile phone app business, alongside grants and subsidies totalling €950,000 (£700,000) and substantial investment worth €200,000 (£145,000).

Funding requirement9 YARDS needs €1 million (£735,000) to achieve its overall goal of becoming the global market leader for mobile OCR in the next 18 months.

9 YARDS GmbHAnylineFunding requirement €1 million (£735,000)Contact Mr Lukas KinigadnerE lukas@anyline.ioT +43 660 5671 549W www.anyline.ioIncorporation date 2013Location Vienna, Austria

#AustrianPitchingDay

I3A TECHNOLOGIES is an independent project within BRAINCON. It addresses existing problems in the early detection, assessment and tracking of not only rheu-matic diseases (RDs) such as osteoarthritis (OA) and rheumatoid arthritis (RA) but also degenerative bone diseases like osteoporosis (OP). The application offers a unique in-depth diagnosis of the condition of the knee joint and surrounding subchondral bone area. For better reproducibility of the examination, a patented knee positioning device has been developed along with the software application.

BRAINCON is in development of a novel set of bone micro architecture analysis algorithms which allow an early prediction of the disease using conventional (and inexpensive) 2D x-ray images.

Previous funds raisedBRAINCON has received federal/state funding from both the Austrian Research Promotion Agency and the Vienna Business Agency, amounting to about €1.3 mil-lion (£940,000).

Funding requirementFuture funding needs (R&D, sales and marketing) are in the €3.5 – €5 million (£2.6 – £3.6 million) range, and should cover the next two to three years.

Braincon Handels-GmbHi3a TechnologiesFunding requirement €3.5 – €5 million (£2.6 – £3.6 million)Contact Mr Richard LjuharE r.ljuhar@bct.co.atT +43 699 1610 6712W www.i3atec.comIncorporation date November 2015Location Vienna, Austria

#AustrianPitchingDay

SOFASESSION has created an online jamming community that allows musicians to find kindred spirits and connects them in real time. Using SOFASESSION, musi-cians can collaborate and interact musically from remote locations. The company uses proprietary technology for audio generation. It enables high quality, low latency audio sampling and fast peer-to-peer audio streaming in order to reach the data transfer speed necessary for live music interaction.

SOFASESSION is based on a freemium model, allowing musicians to use the basic service for free and purchase additional functionality via a premium subscrip-tion. It serves as a fully integrated solution for music creation – from looking for co-musicians, to the first jam and rehearsal, right up to collaborative recording.

Previous funds raisedSOFASESSION has been funded by equity contributions of the founders €200,000 (£145,000), as well as Austrian state grants and high-tech subsidies €500,000 (£370,000).

Funding requirementThe company needs €500,000 (£370,000) to increase customer acquisition in 2016 and to cover negative operational cost until breaking even.

sofasession GmbHsofasessionFunding requirement €500,000 (£370,000)Contact Mr Helmut HerglotzE h.herglotz@sofasession.comT +43 650 2334 554W www.sofasession.comIncorporation date January 2014Location Vienna, Austria

#AustrianPitchingDay

Many patients naturally associate medical treatments with feelings of anxiety and unease. HAPPYMED is building a system that changes that by helping patients leave the distress of undergoing treatment behind them, turning their treatment into a positive experience. Video glasses and earphones in combination with video content stored on a media centre create a gentle and non-pharmaceutical dis-traction. Within seconds, HAPPYMED is ready to use. Full mobility and a battery life of 12 hours guarantee absolute flexibility in utilisation.

The system is already being used in hospitals (including chemotherapy, dialysis and surgical departments) and by dentists. A major benefit is that it is the first fully self-sufficient audio-visual solution on the market.

Previous funds raisedFor over a year, the founders financed the company themselves. The first round of financing from international angels was completed in early 2015, allowing the first version of the product to be launched onto the market by the middle of the year.

Funding requirementThe upcoming seed round, amounting to €350,000 – €580,000 (£250,000 – £800,000), is intended to finance the large-scale production of the enhanced, second version of HAPPYMED. This will pave the way to enter Europe’s most promising markets.

HappyMed GmbHHappyMed video glassesFunding requirement €350,00 – €800,000 (£250,000 – £580,000)Contact Mr Philipp AlbrechtE pa@happymed.orgT +43 680 1128 061W www.happymed.orgIncorporation date January 2014Location Vienna, Austria

#AustrianPitchingDay

With its PITCHSCORING and DEALSCREENING products, DEALMATRIX has two innovative solutions and services that allow investors, corporates, event organ-isers and start-ups to increase efficiency and deepen market insights.

PITCHSCORING is a mobile app that visualizes the fit of a target-company with the individual investment-scope and risk-profile of investors. The app provides easy to use services for scoring, venture news, statistics and benchmarking.

DEALSCREENING is a SaaS / Fintech solution that simplifies private equity (ven-ture) investment and corporate “scouting”. It provides innovative services for work-flow optimisation, market data, network and relevant news flow. The soft-ware offers solutions for receiving, screening, processing and evaluating appli-cations from capital-seeking companies in an efficient, intuitive, easy-to-handle and customisable way.

DEALMATRIX also entirely automates report generation and co-operation with experts. All communication data between investors and companies – including correspondence, due diligence documents and working materials – is automati-cally stored in a secure and easy-to-manage data room.

Previous funds raisedSince the original idea was born in 2013, €200,000 (£145,000) has been invested by the founders. DEALSCREENING has already raised €37,000 (£26,000).

Funding requirementA funding round of €500,000 (£370,000) is currently underway.

DealMatrix GmbHPitchscoring, DealscreeningFunding requirement €500,000 (£370,000)Contact Mr Christoph DrescherE christoph.drescher@dealscreening.comT +43 677 6122 2575W www.dealscreening.comIncorporation date November 2015Location Vienna, Austria

#AustrianPitchingDay

NOTES

Powered by

In cooperation with